ArticleJournal of Ayurveda and integrative medicine
The systemic anti-diabetic effect of polyherbal formulation Varanadi Kashayam is mediated through GLP-1 secretion and DPP4 inhibition.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrontiers of health science increasingly emphasize systems and network medicine approaches for managing complex lifestyle diseases such as diabetes. In this context, systemic targets like incretin hormones and their modulators, particularly DPP4 inhibitors have gained prominence. Ayurveda, the Indian System of Medicine, with its clinically validated multicomponent formulations, offers a valuable resource for integrative therapeutic strategies with systemic mode of action.
objectivesThe study investigates the incretin modulatory effect of Varanadi Kashayam (VA), an Ayurveda polyherbal formulation used in the clinical management of diabetes and its comorbidities.
methodsA high-fat diet and low dose STZ-induced Sprague-Dawley (SD) rat model was used to study anti-diabetic, GLP-1 secretory, and anti-obesity effects of VA. In vitro studies using GLUTag cells assessed GLP-1 secretion and DPP4 gene expression modulation; and studies using 3T3-L1 fibroblasts examined anti-adipogenic effects. Computational methods including molecular docking and molecular dynamic simulations identified phytochemicals potentially contributing to DPP4 inhibition.
resultsVA administration significantly improved fasting blood glucose and oral glucose tolerance in experimental animals, along with enhanced GLP-1 secretion. In vitro results showed significant inhibition of DPP4 enzyme activity, increased GLP-1 secretion, and downregulation of DPP4 gene expression in GLUTag cells, and suppression of adipogenesis in 3T3-L1 fibroblasts. Computational analyses ascertained Chebulinic acid, Chebulagic acid, and Terchebin as top-ranked phytochemicals that could potentially inhibit DPP4.
conclusionCombining in vitro, in vivo, and in silico findings, this study provides valuable insight into the incretin modulatory effect of VA in treating diabetes and associated metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.